Cyclophosphamide

Welcome to Dwaey, specifically on Cyclophosphamide page.
This medicine contains important and useful components, as it consists of
Cyclophosphamide is available in the market in concentration.

Generic Name of Cyclophosphamide - Learn More

Cyclophosphamide

Cyclophosphamide Precaution - What You Need to Know

Before initiating Cyclophosphamide therapy, it is essential for patients to consult with their healthcare provider to ensure the drug is safe and appropriate for their specific condition. Key precautions include:

- Bone Marrow Suppression: Cyclophosphamide is known to cause myelosuppression, which leads to a reduction in the production of blood cells. This can result in anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count). Regular monitoring of blood counts is essential during treatment.
- Hydration: Cyclophosphamide can cause hemorrhagic cystitis, which is bladder inflammation and bleeding due to the accumulation of its toxic metabolites. Adequate hydration and administration of mesna (a protective agent) can reduce the risk.
- Infections: As Cyclophosphamide suppresses immune function, patients are at increased risk of infections, including bacterial, viral, and fungal infections. Prompt treatment and infection prophylaxis may be necessary during therapy.
- Fertility and Reproductive Health: Cyclophosphamide can cause infertility in both men and women, with potential long-term effects. It may lead to ovarian failure in women and testicular atrophy in men. It is recommended to discuss fertility preservation options before starting therapy.
- Pregnancy and Breastfeeding: Cyclophosphamide is Category D for pregnancy, meaning it can harm the fetus. It should be avoided during pregnancy unless absolutely necessary. The drug is also contraindicated during breastfeeding, as it may pass into breast milk and harm the infant.
- Cardiovascular Effects: Cyclophosphamide has the potential to cause cardiomyopathy and heart failure in some patients, particularly those who have received high doses or prolonged therapy. Cardiac monitoring may be required in such cases.
- Secondary Malignancies: Long-term use of Cyclophosphamide has been associated with an increased risk of developing secondary cancers, such as leukemia and lymphoma.

Cyclophosphamide Indication - Uses and Benefits

Cyclophosphamide is primarily indicated for the treatment of various types of cancer and certain autoimmune conditions:

- Cancer Treatment:
- Lymphomas (e.g., Hodgkin’s lymphoma and non-Hodgkin’s lymphoma)
- Leukemias (e.g., acute lymphoblastic leukemia, chronic lymphocytic leukemia)
- Breast Cancer: Cyclophosphamide is frequently used as part of a combination chemotherapy regimen to treat breast cancer.
- Ovarian Cancer: It is used for treating ovarian carcinoma, often in combination with other chemotherapy agents.
- Sarcomas: Including soft tissue sarcomas and osteosarcoma.
- Testicular Cancer: Cyclophosphamide is used for certain testicular cancers as part of combination therapy.
- Other Cancers: It is also used for gastric cancer, lung cancer, cervical cancer, and others, often in combination with other chemotherapeutic agents.

- Autoimmune Diseases:
- Systemic Lupus Erythematosus (SLE): Cyclophosphamide is sometimes used to treat severe cases of SLE, particularly when the kidney or central nervous system is involved.
- Rheumatoid Arthritis: It is used in severe, refractory cases of rheumatoid arthritis.
- Other Conditions: It may also be used in vasculitis, myasthenia gravis, and other autoimmune disorders when conventional therapies have failed.

Cyclophosphamide Contraindications - Important Warnings

Cyclophosphamide is contraindicated in certain conditions where its use could be harmful:

- Hypersensitivity: Patients with known hypersensitivity or allergic reactions to Cyclophosphamide or its components should not be given the drug.
- Severe Bone Marrow Suppression: Cyclophosphamide is contraindicated in patients who already have significant bone marrow suppression due to previous chemotherapy or pre-existing conditions.
- Severe Hepatic Impairment: Cyclophosphamide should be avoided in patients with severe liver disease, as it can worsen liver dysfunction and increase the risk of toxicities.
- Severe Renal Impairment: Patients with severe renal dysfunction (e.g., CrCl < 30 mL/min) should not receive Cyclophosphamide without careful consideration and dose adjustment, as it is excreted primarily through the kidneys.
- Pregnancy: Cyclophosphamide is a Category D drug and should not be used during pregnancy, especially during the first trimester, as it can cause fetal harm, including malformations and developmental issues.
- Lactation: Cyclophosphamide is contraindicated in breastfeeding women because it passes into breast milk and can harm the infant.

Cyclophosphamide Side Effects - What to Expect

Cyclophosphamide can cause a wide range of side effects, some of which can be severe:

- Common Side Effects:
- Nausea and vomiting (often managed with antiemetic therapy)
- Hair loss (alopecia)
- Fatigue and weakness
- Mouth sores (mucositis)
- Loss of appetite
- Increased risk of infections due to immunosuppression
- Diarrhea or constipation
- Skin rash or changes in skin color

- Severe Side Effects:
- Bone Marrow Suppression: Manifested as leukopenia, anemia, and thrombocytopenia, increasing the risk of bleeding and infection.
- Hemorrhagic Cystitis: Cyclophosphamide can cause inflammation and bleeding in the bladder. Symptoms include painful urination, blood in the urine, and bladder discomfort.
- Cardiotoxicity: High doses of Cyclophosphamide can lead to cardiomyopathy and heart failure, particularly with prolonged use.
- Secondary Malignancies: There is a risk of developing secondary cancers, such as leukemia and bladder cancer, after prolonged Cyclophosphamide therapy.
- Fertility Issues: Cyclophosphamide can cause infertility, and this risk is especially high with long-term use or high doses. Both men and women should discuss fertility preservation options before starting therapy.
- Liver Toxicity: Liver enzyme elevations or hepatitis can occur, particularly in patients with pre-existing liver conditions.

Patients should immediately inform their healthcare provider if they experience severe side effects such as persistent fever, bleeding, chest pain, or difficulty urinating.

Cyclophosphamide Pregnancy Category ID - Safety Information

4

Cyclophosphamide Mode of Action - How It Works

Cyclophosphamide is a chemotherapeutic agent that works by interfering with the DNA in rapidly dividing cells, leading to their destruction. Its mechanism of action involves:

- DNA Alkylation: Cyclophosphamide is metabolized in the liver to phosphoramide mustard, which is the active metabolite. This metabolite binds to the DNA in cancer cells, forming cross-links between DNA strands. This prevents the DNA from unwinding, which is essential for replication and transcription, ultimately leading to cell death.
- Cell Cycle Arrest: Cyclophosphamide induces cell cycle arrest, particularly in the S-phase, where DNA replication occurs. It can also trigger apoptosis (programmed cell death) in malignant cells.
- Selective Toxicity: While Cyclophosphamide affects all rapidly dividing cells, the drug primarily targets cancer cells due to their faster growth rate compared to normal cells.

Cyclophosphamide Drug Interactions - What to Avoid

Cyclophosphamide interacts with several drugs and substances that can alter its effectiveness and increase the risk of side effects:

- Bone Marrow Suppressants: When used in combination with other myelosuppressive agents (e.g., methotrexate, azathioprine, cisplatin), the risk of severe bone marrow suppression increases significantly.
- Allopurinol: Used to prevent tumor lysis syndrome in some cancer patients, allopurinol can increase the blood levels of Cyclophosphamide, enhancing its toxicity.
- Anticoagulants: Cyclophosphamide may increase the effects of oral anticoagulants, such as warfarin, raising the risk of bleeding. Patients should have their INR monitored closely.
- Phenytoin: Cyclophosphamide may reduce the effectiveness of phenytoin (an anticonvulsant), requiring dose adjustments and monitoring.
- Live Vaccines: As Cyclophosphamide suppresses the immune system, patients should avoid live vaccines during treatment, as this can lead to an increased risk of infections.

Cyclophosphamide Adult Dose - Recommended Dosage

The dose of Cyclophosphamide varies depending on the type of cancer being treated and whether the drug is used alone or in combination with other therapies. Common dosing regimens include:

- Cancer Treatment: The typical intravenous dose for adult patients is 40-50 mg/kg (body surface area) once every 2-4 weeks, adjusted based on clinical response and toxicity. For combination regimens, doses may be lower.
- Autoimmune Disorders: For diseases like systemic lupus erythematosus (SLE), the dose may range from 0.5 to 1 mg/kg daily or administered in pulses, depending on disease severity and response.

Cyclophosphamide Child Dose - Dosage for Children

Cyclophosphamide dosing in pediatric patients is generally based on body surface area (BSA) or weight, and doses vary based on the condition being treated:

- Cancer Treatment: Pediatric doses for cancer therapy generally range from 30-50 mg/kg every 2-4 weeks, depending on the type of cancer and the use of other chemotherapeutic agents.
- Autoimmune Diseases: The pediatric dose for autoimmune conditions like SLE typically starts at 1 mg/kg daily or in pulse regimens.

As always, healthcare providers should determine the exact dosage based on the child's specific needs, clinical condition, and response to treatment.

Cyclophosphamide Renal Dose - Dosage for Kidney Conditions

Cyclophosphamide is primarily excreted via the kidneys, so renal dose adjustments are necessary for patients with renal impairment:

- Mild to Moderate Renal Impairment: Dose adjustments may be required for patients with CrCl between 30-60 mL/min, and careful monitoring for signs of toxicity should be performed.
- Severe Renal Impairment: Cyclophosphamide should be used with extreme caution or avoided in patients with CrCl < 30 mL/min unless absolutely necessary, as there is a high risk of accumulation and severe toxicity.